ClinicalTrials.gg
CompletedNCT06381986Updated Aug 22, 2025Results posted

Efficacy and Safety of SHJ002 Ophthalmic Solution in the Treatment of Corneal Erosion in Sjogren's Patients

A Phase 2 interventional study of SHJ002 and Vehicle in Corneal Erosion, sponsored by Sunhawk Vision Biotech, Inc.. Completed at 6 sites in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Sunhawk Vision Biotech, Inc. · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to measure efficacy and safety with 0.25% SHJ002 sterile ophthalmic solution compared to vehicle in treating corneal erosion in Sjogren's patients.

SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.

Read the detailed description

Participants will be randomized to treatment with SHJ002 Ophthalmic Solution or vehicle which will be administered to each eye twice daily for 12 weeks.

02

Conditions studied

  • Corneal Erosion

Keywords

  • Corneal Erosion
03

In context

Lead sponsor

Sunhawk Vision Biotech, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants 18 years of age or older inclusive, at the time of signing the .
  2. Diagnosis with Sjogren's syndrome and have corneal erosion
  3. Female participants must be 1 year , surgically sterilized, or females of with a negative urine pregnancy test

Exclusion criteria

Exclusion Criteria:

  1. Ocular surface corneal disease, other than corneal erosion and dry eye disease (DED).
  2. Lid margin disorder other than meibomian gland dysfunction (MGD)
  3. Presence of any ocular condition
  4. Any history of eyelid surgery or intraocular/ocular surgery
  5. Cauterization of the punctum or punctal plug
  6. Use of lid scrubs containing chemicals or baby shampoo, or eyelid makeup
  7. Use of any of the drugs medications
  8. Any changes in the dosing of any chronically used systemic drug
  9. Disease, condition, or disorder that in the judgement of Investigator could confound study assessments or limit compliance to study protocol
  10. Known history of alcohol and/or drug abuse within 12 months
  11. Known allergy or contraindication to any component of product (IP) formulation or diagnostic agents.
  12. Participation in any drug or device clinical investigation within 30 days
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
116 participants (actual)

Study arms

  • Experimental
    SHJ002

    SHJ002 Ophthalmic Solution: topically administered to each eye twice daily for 12 weeks

    Drug: SHJ002

  • Placebo comparator
    Vehicle

    Vehicle: topically administered to each eye twice daily for 12 weeks

    Other: Vehicle

Interventions

  • DrugSHJ002

    Topical ophthalmic

  • OtherVehicle

    Topical ophthalmic

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in Total Corneal Fluorescein Staining

    The total corneal fluorescein staining score will be assessed using the NEI grading scale (0-15 points; higher scores indicate more severe staining).

    Time frame: Baseline to Week 12

Secondary outcomes

  1. Change From Baseline to Week 12 in Inferior Corneal Fluorescein Staining (iCFS)

    iCFS score will be assessed using NEI regional grading (0-3 for the inferior region); higher scores represent more severe staining.

    Time frame: Baseline to Week 12

  2. Change From Baseline to Week 12 in SANDE Score

    Symptom Assessment in Dry Eye (SANDE) questionnaire total score, on a 0-100 scale (higher = worse symptoms).

    Time frame: Baseline to Week 12

07

Results

Posted Aug 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneSHJ002Vehicle
Started5858
Completed5451
Not completed47

Outcome measures

PrimaryChange From Baseline to Week 12 in Total Corneal Fluorescein Staining

The total corneal fluorescein staining score will be assessed using the NEI grading scale (0-15 points; higher scores indicate more severe staining).

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline to Week 12 in Total Corneal Fluorescein Staining
units on a scaleSHJ002Vehicle
Change From Baseline to Week 12 in Total Corneal Fluorescein Staining-2.55 (-3.43 to -1.68)-0.37 (-1.23 to 0.49)
SecondaryChange From Baseline to Week 12 in Inferior Corneal Fluorescein Staining (iCFS)

iCFS score will be assessed using NEI regional grading (0-3 for the inferior region); higher scores represent more severe staining.

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in Inferior Corneal Fluorescein Staining (iCFS)
score on a scaleSHJ002Vehicle
Change From Baseline to Week 12 in Inferior Corneal Fluorescein Staining (iCFS)-0.79 (-1.07 to -0.52)-0.14 (-0.41 to 0.13)
SecondaryChange From Baseline to Week 12 in SANDE Score

Symptom Assessment in Dry Eye (SANDE) questionnaire total score, on a 0-100 scale (higher = worse symptoms).

Time frame:
Baseline to Week 12
Reported as:
Least squares mean · score on a scale
Change From Baseline to Week 12 in SANDE Score
score on a scaleSHJ002Vehicle
Change From Baseline to Week 12 in SANDE Score-31.21 (-41.21 to -21.21)-28.87 (-38.15 to -19.59)

Adverse events

Collected over 84 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SHJ0020/58 (0%)0/58 (0%)0/58 (0%)
Vehicle0/58 (0%)0/58 (0%)0/58 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)SHJ002VehicleTotal
Mean60.95 ± 9.4361.12 ± 10.9661.03 ± 10.18
Sex: Female, Male
Sex: Female, Male(Participants)SHJ002VehicleTotal
Female5655111
Male235
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SHJ002VehicleTotal
American Indian or Alaska Native000
Asian5858116
Native Hawaiian or Other Pacific Islander000
Black or African American000
White000
More than one race000
Unknown or Not Reported000
08

Study locations

6 sites
  • Kaohsiung Medical Chung-Ho Memorial Hospital
    Kaohsiung City, 807, Taiwan
  • Kaohsiung Veterans General Hospital
    Kaohsiung City, 81341, Taiwan
  • Chang Gung Memorial Hospital-Tu Cheng
    New Taipei City, 236, Taiwan
  • MacKay Memorial Hospital
    Taipei, 10449, Taiwan
  • Cathay General Hospital
    Taipei, 106, Taiwan
  • Tri-Service General Hospital
    Taipei, 11490, Taiwan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2024 to primary completion in Apr 2025, 9 months.

Results were first posted in Aug 2025, 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 24, 2024
StartActual
Jun 28, 2024
Primary completionActual
Apr 10, 2025
CompletionActual
Apr 17, 2025
Results first posted
Aug 22, 2025
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06381986
Lead sponsor
Sunhawk Vision Biotech, Inc.
Responsible party
Sponsor
First posted
Apr 24, 2024
Start date
Jun 28, 2024
Primary completion
Apr 10, 2025
Completion
Apr 17, 2025
Results posted
Aug 22, 2025
Last update
Aug 22, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion